Author

B. Snijder

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 3 Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 3 Approach:statistical model· 3 Organism:mouse· 2 Assay:multiome· 2

Frequent Co-Authors

T. Weiss· 3 shared A. Buck· 2 shared D. Kaymak· 2 shared G. Hutter· 2 shared H. Laubli· 2 shared J. Mena· 2 shared M. McDaid· 2 shared M. Weller· 2 shared

Activity by Year

2019-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

T. Weiss

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker

T. A. Martins, N. Tatari, D. Kaymak, S. Hogan, E. M. Bartoszek, R. Wieboldt, M.-F. Ritz, A. Buck, M. McDaid, A. Gerber, A. Beshirova, M. M. Etter, A. Heider, T. Shekarian, H. Mohamed, , G. Hutter

This paper develops a CAR T cell therapy that secretes a CD47 blocker to enhance anti-EGFRvIII efficacy against glioblastoma by modulating the tumor microenvironment.

bioRxiv · Aug 31, 2023Cancer Biology

The Siglec-sialic acid-axis is a target for innate immunotherapy of glioblastoma

P. Schmassmann, J. Roux, A. Buck, N. Tatari, S. Hogan, J. Wang, S. Lee, B. Snijder, T. A. Martins, M.-F. Ritz, T. Shekarian, D. Kaymak, M. McDaid, M. Weller, T. Weiss, , G. Hutter

This study identifies the Siglec-sialic acid-axis as a target for innate immunotherapy in glioblastoma, showing that blocking Siglec-E enhances phagocytosis and T cell priming, leading to delayed tumor growth and prolonged survival.

bioRxiv · Nov 7, 2022Cancer Biology

ROS induction as a strategy to target persister cancer cells with low metabolic activity in NRAS mutated melanoma

O. M. Eichhoff, C. I. Stoffel, J. Kaesler, L. Briker, P. Turko, G. Karsai, N. Zila, V. Paulitschke, P. F. Cheng, A. Leitner, A. Bileck, N. Zamboni, A. Irmisch, Z. Balazs, A. Tastanova, , M. Levesque

The paper identifies ROS induction as a strategy to target MEK-inhibitor resistant NRAS-mutated melanoma cells by exploiting their quiescent metabolic state and elevated baseline ROS levels.

bioRxiv · Oct 19, 2022 · PreprintCancer Biology

Targeting tumour-intrinsic neural vulnerabilities of glioblastoma

S. Lee, T. Weiss, M. Buehler, J. Mena, Z. Lottenbach, R. Wegmann, M. Sun, M. Bihl, B. Augustynek, S. Baumann, S. Goetze, A. van Drogen, P. Pedrioli, D. Kirschenbaum, F. Vasella, , B. Snijder

This study identifies neural vulnerabilities in glioblastoma by analyzing patient samples and model systems, revealing drug targets and pathways that can be exploited for treatment.

bioRxiv · Oct 7, 2022 · PreprintCancer Biology

Critical Nodes of Virus-Host Interaction Revealed Through an Integrated Network Analysis

K. Bosl, A. Ianevski, T. T. Than, P. I. Andersen, S. Kuivanen, M. Teppor, E. Zusinaite, U. Dumpis, A. Vitkauskiene, R. J. Cox, H. Kallio-Kokko, A. Bergqvist, T. Tenson, V. Oksenych, M. Bjoras, , R. K. Kandasamy

This study identifies critical host-virus interaction nodes through network analysis and drug re-purposing, revealing key targets for antiviral therapies.

bioRxiv · Feb 13, 2019 · PreprintImmunology